Trials / Withdrawn
WithdrawnNCT00061178
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy & Safety of rhuMAb VEGF in Previously Treated Metastatic Renal Cell Carcinoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhuMAb VEGF (Bevacizumab) |
Timeline
- First posted
- 2003-05-23
- Last updated
- 2016-10-19
Source: ClinicalTrials.gov record NCT00061178. Inclusion in this directory is not an endorsement.